From Yonsei E1 Plastic Surgery Clinic; Samsung Feel Clinic; Samsung Lohas Clinic; Korea Leaders Medical Group; Regen Clinic; and the Department of Plastic and Reconstructive Surgery, Hanyang University Seoul Hospital, Hanyang University, College of Medicine.
Plast Reconstr Surg. 2019 Jul;144(1):137-143. doi: 10.1097/PRS.0000000000005716.
Blindness caused by soft-tissue filler injection is the most tragic complication, with no standard treatments until recently. Retrobulbar hyaluronidase injection has been proposed as the treatment, but its effectiveness in visual compromise remains to be determined. The authors aimed to determine the effectiveness of retrobulbar hyaluronidase using soft-tissue filler in an iatrogenic blindness animal model.
New Zealand White rabbits were used to simulate the hyaluronic acid-associated vascular occlusion model. A volume of 0.7 to 1.6 ml of hyaluronic acid filler was injected into the internal carotid artery to create a retinal artery occlusion. The rabbits were administered retrobulbar hyaluronidase (3000 IU) at different postobstruction time points (5 and 10 minutes). No intervention was given to the control group. Fundus photography was performed before and immediately after the filler injection and immediately after the administration of retrobulbar hyaluronidase. Electroretinography was performed after 60 minutes to confirm the retinal reperfusion and electrophysiologic function.
All of the experimental eyes recorded total occlusion after hyaluronic acid injection. Three eyes with a completely occluded retinal artery following retrobulbar hyaluronidase treatment showed improved retinal reperfusion by fundus photography and corresponding electroretinography. Despite administration of the retrobulbar hyaluronidase injection, one completely occluded eye showed no improvement in perfusion. All of the control eyes recorded complete occlusion 1 hour after hyaluronic acid filler injection.
Retrobulbar hyaluronidase may be an effective evidence-based treatment option for humans. Hyaluronidase concentration and injection time are the important factors for faster recovery, but additional studies are still required.
由软组织填充物注射引起的失明是最悲惨的并发症,直到最近才没有标准的治疗方法。玻璃体内注射透明质酸酶已被提议作为治疗方法,但它在视力受损方面的有效性仍有待确定。作者旨在确定玻璃体内注射透明质酸酶治疗因软组织填充物引起的失明的有效性。
新西兰白兔用于模拟透明质酸相关血管阻塞模型。将 0.7 至 1.6 毫升的透明质酸填充物注入颈内动脉以造成视网膜动脉阻塞。在不同的阻塞后时间点(5 分钟和 10 分钟),向兔子注射玻璃体内透明质酸酶(3000IU)。对照组未进行干预。在填充物注射前和注射后立即以及玻璃体内透明质酸酶注射后立即进行眼底摄影。在 60 分钟后进行视网膜电图检查以确认视网膜再灌注和电生理功能。
所有实验眼在透明质酸注射后均记录完全阻塞。在玻璃体内注射透明质酸酶治疗后,3 只完全阻塞的视网膜动脉的眼通过眼底摄影和相应的视网膜电图显示出改善的视网膜再灌注。尽管进行了玻璃体内透明质酸酶注射,但一只完全阻塞的眼的灌注无改善。所有对照眼在透明质酸填充物注射后 1 小时均记录完全阻塞。
玻璃体内透明质酸酶可能是一种有效的基于证据的人类治疗选择。透明质酸酶浓度和注射时间是更快恢复的重要因素,但仍需要进一步的研究。